

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The goal of the MINDACT trial, for which initial results were recently published, was to evaluate the benefit of genomic profiling with the _____ in addition to standard clinical-pathological criteria for patients with early-stage breast cancer (BC) and 0 to 3 positive lymph nodes who might safely forgo chemotherapy without compromising their outcome.
 - Breast Cancer Index
 - 70-gene signature
 - 21-gene signature
- Recent ASCO guidelines regarding the use of the 21-gene Recurrence Score® to guide adjuvant systemic therapy decisions recommend using the assay for patients with ER-positive, node-positive BC.
 - True
 - False
- The Phase III SANDPIPER study is investigating the addition of _____ to fulvestrant for patients with ER-positive, advanced BC that has progressed on aromatase inhibitors.
 - Alpelisib
 - Taselisib
 - Abemaciclib
 - None of the above
- Activating mutations in the ESR1 gene occur in about 10% to 20% of patients with ER-positive BC and are associated with resistance to standard hormonal therapies.
 - True
 - False
- The Phase III MA17R trial evaluating the extension of adjuvant letrozole for 5 years after the completion of an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage BC demonstrated a significant improvement in _____ with the extension of aromatase inhibitor therapy.
 - Disease-free survival
 - Overall survival
 - Both a and b
- In the treatment of ER-positive metastatic BC (mBC), abemaciclib _____.
 - More potently inhibits CDK4 than CDK6
 - Does not have single-agent activity
 - Is associated predominantly with gastrointestinal toxicities
 - All of the above
 - Both a and c
- The Phase III HERITAGE trial of the proposed trastuzumab biosimilar Myl-14010 versus trastuzumab in combination with a taxane for HER2-positive mBC demonstrated _____.
 - An equivalent overall response rate
 - Similar immunogenicity
 - No difference in LVEF between the arms
 - All of the above
- A recent paper investigating the role of the 21-gene signature assay for patients with invasive lobular carcinoma reported that approximately a third of the patients received Recurrence Scores placing them in the intermediate-risk category and that patients in this group were significantly more likely to receive chemotherapy than those in the low-risk category.
 - True
 - False
- The Phase III PALOMA-2 trial evaluating palbociclib with letrozole versus letrozole alone for patients with ER-positive, HER2-negative, advanced BC who had not received prior systemic therapy for their advanced disease demonstrated a significant improvement in _____ with the combination.
 - Progression-free survival
 - Objective response rate
 - Both a and b
 - Neither a nor b
- Pertuzumab has been approved by the FDA, in combination with trastuzumab and docetaxel, for patients with HER2-positive BC in the _____ setting.
 - Neoadjuvant
 - Metastatic
 - Adjuvant
 - All of the above
 - Both a and b